It has been shown that the adverse reactions of TKI correlate with drug concentrations and metabolic enzyme gene polymorphisms (Liao et al., 2020), such as CYP3A5*3 for sorafenib-related severe hepatic and renal damage (Guo et al., 2018), and CYP3A4-rs4646437 and CYP3A5-rs776746 for sunitinib-related hypertension (Garcia-Donas et al., 2011; Diekstra et al., 2015; Diekstra et al., 2017). This evidence concerns the gene CYP3A5 and hypertensive disorder.